Natera, Inc. (NASDAQ:NTRA) Shares Sold by C WorldWide Group Holding A S

C WorldWide Group Holding A S cut its stake in Natera, Inc. (NASDAQ:NTRA) by 39.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 200,000 shares of the medical research company’s stock after selling 130,000 shares during the period. Natera accounts for approximately 0.4% of C WorldWide Group Holding A S’s portfolio, making the stock its 27th largest position. C WorldWide Group Holding A S’s holdings in Natera were worth $31,660,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Blue Trust Inc. boosted its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares during the last quarter. Versant Capital Management Inc raised its holdings in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after buying an additional 166 shares during the period. Principal Securities Inc. raised its holdings in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after buying an additional 59 shares during the period. Covestor Ltd raised its holdings in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. Finally, Global Retirement Partners LLC raised its holdings in Natera by 55.0% in the fourth quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company’s stock valued at $69,000 after buying an additional 154 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTRA has been the topic of several research reports. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Canaccord Genuity Group raised their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a report on Friday, January 3rd. TD Cowen lifted their price objective on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum lifted their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Guggenheim lifted their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $170.94.

Natera Stock Down 3.5 %

Shares of NASDAQ:NTRA opened at $162.31 on Monday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $167.98 and a 200 day simple moving average of $145.85. The firm has a market cap of $21.43 billion, a PE ratio of -92.22 and a beta of 1.66. Natera, Inc. has a 12-month low of $69.74 and a 12-month high of $183.00.

Insider Buying and Selling

In other Natera news, insider John Fesko sold 669 shares of Natera stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares of the company’s stock, valued at $18,217,063.20. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the transaction, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. This represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 295,772 shares of company stock worth $49,741,699. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.